Clinical trials have shown that RANKL inhibitors, such as denosumab, are effective in reducing bone remodeling, increasing bone mineral density, and lowering the incidence of fractures in postmenopausal women with osteoporosis [6,7]. Here, TNFSF11 is linked to osteoporosis.